Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can your smartwatch replace the blood pressure cuff?

NCT ID NCT06573801

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checked if two wrist-worn cuffless blood pressure devices (Aktiia and Healthstats BPro Evo) give readings that match the standard arm-cuff monitor worn for 24 hours. 48 adults wore each device alongside the standard monitor. The goal is to see if these wearable devices are reliable enough for everyday blood pressure tracking.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

48 people

The number who actually took part.

Started

Jan 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant is aged ≥21 years and \<85 years at the time of screening visit. 2. Able to speak and understand English. 3. Able and willing to give informed consent. 4. Independent and mobile. 5. Willing and able to wear devices/no upper limb restrictions. Exclusion Criteria: 1. Individuals who are or have been involved in interventional research within a period of 3 months. 2. Vulnerable individuals including those with mental ill-health or who are care dependant. 3. Individuals with serious comorbidities or end organ damage (e.g., previously diagnosed heart failure with New York Heart Association class III/IV, verbal or documented evidence of renal failure or history of dialysis, stroke or myocardial infarction within the last 1-year, previous stroke with residual deficit); and doctor diagnosed hyperthyroidism. 4. Individuals with arterio-venous fistula; or reduced peripheral perfusion identified by a history of Raynaud's syndrome or a pulse pressure of \<30mmHg or a capillary refill time of \>3s in the dominant arm. 5. Individuals with heart rhythm disorders e.g., persistent Atrial Fibrillation and those who have tachycardia \> 120 after 5 minutes of rest. 6. Individuals with skin irritation injury or damage. 7. Self-reported pregnancy. Participation will be withdrawn in the event of pregnancy following enrolment. 8. Life threatening or terminal illness with limited lifespan of \<12months. 9. Obesity (Body Mass Index 35kg/m2 or higher) or arm/wrist circumferences outside the range highlighted in each device's specification. 10. Those with very high office BP (greater than Stage 3 hypertension). 11. Interarm difference \>15mmHg in Systolic BP and \>10mmHg in Diastolic BP. 12. Where the PI thinks that it would be technically difficult to obtain or interpret blood pressures measurements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood pressure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ajay K Gupta

    London, EC1M 6BQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.